Ma Jiyan, Yang Yang, Huang Yangmu
Emerg Infect Dis. 2025 Jan;31(1):14-21. doi: 10.3201/eid3101.230638.
Since the severe acute respiratory syndrome outbreak in 2003, China has invested substantial efforts in promoting scientific and technological advances for medical countermeasures against high-threat pathogens. The examination of China's landscape identifies progress and gaps in research and development (R&D) and also highlights management and regulatory issues that should be of concern to other countries. Our study examined the current state of R&D of medical countermeasures in China during 1990-2022. The findings showed a robust and diversified pipeline responding quickly to disease outbreaks and policy changes. However, proactive and highly innovative candidates are limited, and a large proportion of vaccines and drugs stagnate at the early development stage. A paradigm shift involving a preemptive R&D agenda and persistent investment, innovative technology development, and accelerated research translation is urgently needed to prepare for the next pandemic.
自2003年严重急性呼吸综合征爆发以来，中国在推动针对高威胁病原体的医学应对措施的科技进步方面投入了大量精力。对中国情况的审视确定了研发方面的进展与差距，也突显了其他国家应关注的管理和监管问题。我们的研究考察了1990年至2022年期间中国医学应对措施的研发现状。研究结果显示，有一个强大且多样化的研发流程能够快速应对疾病爆发和政策变化。然而，积极主动且极具创新性的候选项目有限，很大一部分疫苗和药物停滞在早期研发阶段。迫切需要进行范式转变，包括制定先发制人的研发议程并持续投入、开发创新技术以及加速研究成果转化，以应对下一次大流行。
